COVID-19 Resources and Projects

In 2020, researchers across UC Berkeley redirected their investigations to address the challenges of the COVID-19 crisis. Learn about all the ways our experts offered solutions across disciplines.


University technology transfer made significant contributions to fighting COVID-19 while ensuring global access (Healthcare Policy 17(4) May 2022). For example, UC Berkeley, which started incorporating global health provisions in its license agreements as early as 2003 to facilitate affordable access to its innovations in low- and middle-income countries, discovered a new implementation of CRISPR. The inclusion of global health protection terms when licensing the technology to Mammoth Biosciences led to the development of a high throughput COVID-19 test, whiich was granted emergency use authorization by the FDA in January 2022.


Photo courtesy of Max & Jules Photography.


Below, you'll find special licensing resources to incentivize rapid utilization of UC Berkeley technologies related to COVID-19, as well as examples of how UC Berkeley partnered with industry to mitigate this pandemic.

Please contact IPIRA for information related to:

  • • Intellectual Property Licensing
  • • Receiving and Sending Materials and Data
  • • Corporate Sponsored Research
  • • Entrepreneurship

For campus policies and resources related to COVID-19, incuding health and safety information, see UC Berkeley's response to the coronavirus outbreak.

Special Intellectual Property Licensing

Industry and academia are collaborating with unprecedented urgency to develop technological solutions in the global fight against the COVID-19 outbreak. UC Berkeley has developed a non-exclusive, royalty-free license template to induce commercial investment in research, development, and commercialization of COVID-19-related life-saving therapeutics and tools.

Corporate Partnerships Addressing COVID-19

The University of California, Berkeley, and the University of Illinois at Urbana-Champaign (UIUC) are the headquarters of a bold research consortium established by enterprise AI software company to leverage the convergence of artificial intelligence (AI), machine learning and the internet of things (IoT) to transform societal-scale systems. In 2020, DTI invested $5.4 million in 26 research projects advancing digital transformation science to mitigate the COVID-19 pandemic. Learn more about the COVID-19 Data Lake, an aggregation of diverse structured and unstructured data sets. Watch for new calls for research proposals.
The Laboratory for Genomics Research is a collaboration between GlaxoSmithKline and the Innovative Genomics Institute, bringing together academic and industrial researchers to accelerate the application of state-of-the-art CRISPR gene-editing techniques. The LGR has funded ten projects at UC Berkeley and UCSF to address COVID-19. Each Excellence in Research Award provides approximately $100,000 in seed funding.



Join the IPIRA Mailing List




Accessibility | Nondiscrimination | Privacy